menu
    • menu

    Company profile for MEDIPOST Co., Ltd

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Since its foundation, the company has stayed on the right course in the midst of countless adversities in stem cell industry and through years of cutting-edge research, MEDIPOST has taken a dominating step in the global biomedical field by achieving market approval of the world’s first allogeneic stem cell drug – CARTISTEM®, in Korea. Biotechnology is believed to be one of the leading industries which will provide a spri...
    Since its foundation, the company has stayed on the right course in the midst of countless adversities in stem cell industry and through years of cutting-edge research, MEDIPOST has taken a dominating step in the global biomedical field by achieving market approval of the world’s first allogeneic stem cell drug – CARTISTEM®, in Korea. Biotechnology is believed to be one of the leading industries which will provide a springboard for korea’s future economic growth. We at MEDIPOST, will continue to do our very best to overcome the current limitations of the treatment paradigm for incurable diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MEDIPOST Co., Ltdkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    644 beon-gil 21, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
    Telephone
    Telephone
    +82 2-3465-6677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.medi-post.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/medipost_en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MediPost Files IND Amendment for FDA Phase 3 Trial
    MediPost Files IND Amendment for FDA Phase 3 Trial

    13 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-13/medipost-inc-submits-ind-amendment-with-us-food-and-drug-administration-to-initiate-phase-iii-tri

    PHARMIWEB
    13 Feb 2026
    Share Share
    MEDIPOST Secures $140M To Advance Late-Stage Clinical Development
    MEDIPOST Secures $140M To Advance Late-Stage Clinical Development

    09 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-09/medipost-inc-announces-140-million-in-funding-to-accelerate-late-stage-clinical-development

    PHARMIWEB
    09 Jan 2026
    Share Share
    MEDIPOST Secures Exclusive License For CARTISTEM In Japan
    MEDIPOST Secures Exclusive License For CARTISTEM In Japan

    19 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medipost-announces-the-exclusive-commercialization-license-agreement-with-teikoku-seiyaku-for-knee-osteoarthritis-treatment-cartistem-in-japan-302646492.html

    PR NEWSWIRE
    19 Dec 2025
    Share Share
    MEDIPOST Advances CARTISTEM® to Phase III in North America
    MEDIPOST Advances CARTISTEM® to Phase III in North America

    03 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241202720121/en

    BUSINESSWIRE
    03 Dec 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search